Home Tags U3-1402

Tag: U3-1402

First Patients Dosed in Phase II Study of Patritumab Deruxtecan in...

A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as U3-1402), a HER3 directed DXd...

Daiichi Sankyo and AstraZeneca to Jointly Evaluate Patritumab Deruxtecan + Osimertinib...

Earlier this week Daiichi Sankyo and AstraZeneca confirmed that the companies had entered into a clinical trial collaboration with to evaluate the combination of...
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Daiichi Sankyo and Gustave Roussy Sign Multi-year and Multi-study Adaptive Phase...

Daiichi Sankyo and Gustave Roussy have signed a multi-year, multi-study research collaboration for the ongoing development of DS-1062 and patritumab deruxtecan (previously known as U3-1402),...

WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and...

The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung cancer (NSCLC) accounts for 80%–90%...
General Views of the 55th Annual Meeting meeting of the American Society of Clinical Oncology. Photo Courtesy: © ASCO/Nick Agro 2019.

Preliminary Phase I Data for U3-1402 Shows Manageable Safety and Reduction...

Preliminary results from the dose escalation part of the phase I study with U3-1402, an investigational and potential first-in-class HER3 targeting antibody-drug conjugate or...

Clinical Trial with Investigational Potential First-in-class HER3-targeting Antibody-drug Conjugate

A first patient has been dosed in a phase I study evaluating the safety and tolerability of U3-1402, in patients with metastatic or unresectable...

Daiichi Sankyo Invests in the Future of Antibody-drug Conjugates

Daiichi Sankyo is making an initial Japanese ¥ 15 billion (US $ 135 million) investment to optimize and enhance its manufacturing capabilities to support...